Experimental vaccine aims to shield transplant patients from Cancer-Causing virus
NCT ID NCT06741072
Summary
This early-stage trial is testing a new vaccine designed to prevent infections from Epstein-Barr virus (EBV) and the cancers it can cause. The study will enroll healthy volunteers and patients awaiting organ transplants, who are at higher risk for EBV-related cancers due to their required immune-suppressing medications. Researchers will give different doses of the experimental vaccine to check its safety and see if it triggers a protective immune response against the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 5 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.